

# SARS-COV-2 NEUTRALIZING ANTIBODY EFFECTIVE AGAINST ALL VARIANTS

[Adams, Lucas](#), [Diamond, Michael](#), [Fremont, Daved](#), [VanBlargan, Laura](#)

[Poranki, Deepika](#)




T-019791

**Disease indication** - SARS-CoV-2 infection (COVID-19)

**Drug format** - Chimeric monoclonal antibody

**Drug class** - Best-in-class

**Research stage and Preliminary data** - The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. The antibody has been extensively tested in hACE2 transgenic mice. The researchers have also performed initial proof of concept experiments against all common SARS-CoV-2 variants (including the South Africa, UK, Brazil, and California variants) *in vitro* to show similar levels of efficacy.



(Left) Cryo-EM depicting the antibody binding site on the SARS-CoV-2 spike protein RBD. (Center, Right) Results of *in vitro* focus-reduction neutralization tests with multiple circulating variants showing minimal change in dose response curves and EC<sub>50</sub> values across variants.

**Target** - SARS-CoV-2 spike protein

**Background** - Mass vaccination is proving to be an effective strategy in combatting the spread of COVID-19. However, the emergence of new variants of SARS-CoV-2 remains a concern, particularly when the new variants show decreased susceptibility to vaccine-generated immune response due to mutations in the spike protein. Therapeutics targeted at conserved regions of the spike protein are ideally suited for use in all variants.

**Mode of action** - This antibody binds the viral spike protein at a highly-conserved epitope, neutralizing the virus by blocking entry at attachment and post-attachment steps.

**Competitive edge** - While other neutralizing antibodies for SARS-CoV-2 have been developed, they often show reduced efficacy on some variants due to mutation of the spike protein. This antibody's epitope is highly conserved across all common variants of SARS-CoV-2, providing effective treatment for all variants.

**Publication** - VanBlargan LA, Adams LJ, Liu Z, Chen RE, Gilchuk P, ... Diamond MS. (2021). [A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope](#). *bioRxiv*.



**WashU**

---

Office of Technology  
Management

**Patent status** - Pending

**Web Links** - Diamond [Profile & Lab](#); Fremont [Profile & Lab](#)